KR950701323A - 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives) - Google Patents

1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives)

Info

Publication number
KR950701323A
KR950701323A KR1019940703815A KR19940703815A KR950701323A KR 950701323 A KR950701323 A KR 950701323A KR 1019940703815 A KR1019940703815 A KR 1019940703815A KR 19940703815 A KR19940703815 A KR 19940703815A KR 950701323 A KR950701323 A KR 950701323A
Authority
KR
South Korea
Prior art keywords
hydrogen
lower alkyl
ring
hydroxy
substituted
Prior art date
Application number
KR1019940703815A
Other languages
English (en)
Other versions
KR100267635B1 (ko
Inventor
뵈게소 클라우스
브레그네달 피터
Original Assignee
존 메이달 피터센
하.룬트베크 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 존 메이달 피터센, 하.룬트베크 아크티에 셀스카브 filed Critical 존 메이달 피터센
Publication of KR950701323A publication Critical patent/KR950701323A/ko
Application granted granted Critical
Publication of KR100267635B1 publication Critical patent/KR100267635B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

일반식 Ⅰ
(상기식에서 X 및 Y는 수소, 할로겐, 트리플루오로메틸, 알킬, 알킬티오, 트리플루오로메틸티오, 알콕시, 히드록시, 알킬술포닐, 아미노, 알킬아미노, 니트로 또는 시아노이며; Ar은 각각 임의적으로 치환된 페닐, 티에닐 또는 푸릴기이며; R1은 수소, 또는 임의적으로 히드록시 치환된 알킬, 알케닐, 시클로알킬 또는 시클로 알킬알킬이며, R2는 알킬, 알케닐, 또는 시클로알킬알킬이거나; 또는 R1과 R2는 함께 피페라진고리와 융합된 5 내지 7원 헤테로환 고리를 형성하는데, 이 고리는 히드록시로치환될 수도 있으며; R3는 수소, 알킬, 알케닐, 시클로알킬 또는 시클로알킬알킬이거나; 또는 R2와 R3는 함께 피페라진고리에 스피로 융합된 3 내지 7원 탄소환 고리를 형성하며; R4는 수소 또는 알킬이다)을 갖는 1-피페라지노-1, 2-디히드로인덴화합물의 트랜스 이성질체는 도파민 D1리셉터에 대한 효능 있는 길항제 작용을 갖는다. 화합물은 중후신경계의 질환, 특히 정신병, 정신분열병(네거티브증상 뿐만아니라 포지티브증상), 불안, 억울증, 수면장해, 편두통, 파킨슨 증후군 또는 코카인 남용의 치료에 유용하다.

Description

1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 일반식 Ⅰ을 갖는 1-피페라지노-1,2-디히드로인덴화합물의 트랜스 이성질체, 그것에 대한 프로드럭 및 약학적으로 허용되는 그것의 산부가염.
    상기식에서 X 및 Y는 독립적으로 수소, 할로겐, 트리플루오로메틸, 저급알킬, 저급알킬티오, 트리플루오로메틸티오, 저급알콕시, 히드록시, 저급알킬술포닐, 아미노, 저급알킬아미노, 저급디알킬아미노, 니트로 및 시아노로부터 선택되며, Ar은 페닐기, 그리고 할로겐, 트리플루오로메틸, 히드록시, 저급알콕시 및 저급알킬로 이루어지는 군으로부터 선택된 하나 이상의 치환기로 치환된 페닐기이거나, 또는 Ar은 티에닐기, 푸릴기 또는 할로겐 또는 저급알킬로 치환된 티에닐 또는 푸릴기이며, R1은 수소, 각각 하나 또는 두 개의 히드록시기로 임의적으로 치환된 저급알킬, 저급 알케닐, 시클로알킬 또는 시클로알킬알킬이며, R2는 저급알킬, 저급알케닐, 시클로알킬 또는 시클로알킬알킬이거나, 또는 R1과 R2가 그것들이 붙어 있는 각각 질소 및 탄소원자와 함께 피페라진 고리와 융합된 5 내지 7원 헤테로환 고리를 형성하는데, 이 헤테로환 고리는 임의적으로 히드록시로 치환될 수도 있으며, R3는 수소, 저급알킬, 저급알케닐, 시클로알킬 또는 시클로알킬알킬이거나, 또는 R2와 R3가 그것들이 붙어 있는 탄소원자와 함께 피페라진 고리에 스피로 융합된 3 내지 7원 탄소환 고리를 형성하며, R4는 수소 또는 저급 알킬이며, 단, R1과 R2가 함께 고리를 형성할때는 R2와 R3는 고리를 형성하지 않는다.
  2. 제1항에 있어서, X가 수소, 할로겐, 저급알킬 또는 트리플루오로메틸이며, Y가 수소 또는 할로겐이며, Ar이 페닐, 할로겐으로 치환된 페닐, 또는 티에닐이며, R1이 수소, 저급알킬, 또는 히드록시로 치환된 저급알킬이며, R2는 저급알킬이거나, 또는 R1과 R2가 그것들이 붙어 있는 각각 질소 및 탄소원자와 함께 피페라진고리와 융합된 피페리디노고리를 형성하는데, 이 피페리디노고리는 임의적으로 히드록시로 치환될 수도 있으며, R3가 수소 또는 저급알킬이거나, 또는 R2와 R3가 그것들이 붙어 있는 탄소원자와 함께 스피로시클로알킬고리를 형성하며, R4가 수소 또는 메틸인 것을 특징으로 하는 화합물.
  3. 제1항에 있어서, X가 수소, 클로로, 브로모, 플루오로원자, 메틸 또는 트리플루오로메틸이며, Y가 수소원자이며, Ar이 페닐, 플루오로페닐 또는 티에닐이며, R1이 수소, 메틸, 2-프로필, 히드록시프로필 또는 히드록시에틸이며, R2는 CH3, 에틸 또는 2-프로필이며 R3는 H, 에틸 또는 메틸이거나, 또는 R2와 R3가 그것들이 붙어 있는 탄소원자와 함께 스피로시클로부틸 또는 스피로시클로펜틸 고리를 형성하며, R4가 수소인 것을 특징으로 하는 화합물.
  4. 약학적으로 허용되는 담체 또는 희석제와 함께 제1항에 따르는 화합물 적어도 한가지로 이루어지는 것을 특징으로 하는 약학제제.
  5. 제4항에 있어서, 제1항에 따르는 화합물이 순수한 거울상체, 라세미체 또는 두 거울 상체의 어떤 다른 혼합물로서 존재하는 것을 특징으로 하는 약학제제.
  6. 치료학적 유효투여량의 제1항에 따르는 화합물을 적합한 담체 또는 희석제와 함께 그것을 필요로 하는 환자에 투여하는 단계로 이루어지는 정신병, 정신분열병(네거티브 증상 뿐만아니라 포지티브증상), 불안, 억울증, 수면장해, 편두통, 파킨슨 증후군 또는 코카인 남용의 치료를 위한 방법.
  7. 정신병, 정신분열병(네거티브 증상 뿐만아니라 포지티브증상), 불안, 억울증, 수면장해, 편두통, 파킨슨증후군 또는 코카인 남용의 치료를 위한 약학제제의 제조를 위한 제1항에 따르는 화합물의 사용.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940703815A 1992-04-28 1993-04-23 1-피페라지노-1, 2-디히드로인덴 유도체 KR100267635B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK92551A DK55192D0 (da) 1992-04-28 1992-04-28 1-piperazino-1,2-dihydroindenderivater
DK551/92 1992-04-28
DK0551/92 1992-04-28
PCT/DK1993/000136 WO1993022293A1 (en) 1992-04-28 1993-04-23 1-piperazino-1,2-dihydroindene derivatives

Publications (2)

Publication Number Publication Date
KR950701323A true KR950701323A (ko) 1995-03-23
KR100267635B1 KR100267635B1 (ko) 2000-11-01

Family

ID=8094828

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703815A KR100267635B1 (ko) 1992-04-28 1993-04-23 1-피페라지노-1, 2-디히드로인덴 유도체

Country Status (24)

Country Link
US (1) US5807855A (ko)
EP (1) EP0638073B1 (ko)
JP (1) JP3255416B2 (ko)
KR (1) KR100267635B1 (ko)
AT (1) ATE194003T1 (ko)
AU (1) AU669709B2 (ko)
CA (1) CA2134566C (ko)
CL (1) CL2003002050A1 (ko)
CZ (1) CZ281676B6 (ko)
DE (1) DE69328901T2 (ko)
DK (2) DK55192D0 (ko)
ES (1) ES2148227T3 (ko)
FI (1) FI113862B (ko)
GR (1) GR3034396T3 (ko)
HK (1) HK1013816A1 (ko)
HU (2) HUT71419A (ko)
IL (1) IL105464A (ko)
NO (1) NO306946B1 (ko)
NZ (1) NZ252098A (ko)
PT (1) PT638073E (ko)
RU (1) RU2114106C1 (ko)
SK (1) SK281613B6 (ko)
WO (1) WO1993022293A1 (ko)
ZA (1) ZA932840B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101386387B1 (ko) * 2005-02-16 2014-04-25 하. 룬드벡 아크티에셀스카브 트랜스-1-((1ｒ,3ｓ)-6-클로로-3-페닐인단-1-일)-3,3-디메틸피페라진의 결정성 염기

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
PT1379520E (pt) * 2001-02-23 2006-08-31 Merck & Co Inc Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
IS7282A (is) * 2001-12-21 2004-05-21 H. Lundbeck A/S Amínóindan afleiður sem serótónín og noradrenalínupptökuhindrar
EP1458704A1 (en) * 2001-12-21 2004-09-22 H. Lundbeck A/S Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
PL199016B1 (pl) † 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
CN101935305B (zh) * 2003-08-18 2013-04-10 H.隆德贝克有限公司 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪及其盐的制备方法及所用中间体
AU2004265021B2 (en) * 2003-08-18 2010-05-27 H. Lundbeck A/S Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
MX2007009816A (es) * 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
NZ589571A (en) * 2008-05-07 2012-07-27 Lundbeck & Co As H Method for treating cognitive deficits using trans-4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine
EP2344163A1 (en) * 2008-10-03 2011-07-20 H. Lundbeck A/S Oral formulation
MX2011011520A (es) * 2009-04-30 2012-06-19 Abbott Gmbh & Co Kg Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfon amida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
DK2639216T3 (en) 2010-11-09 2018-09-24 Kaneka Corp Halogenated Indones and Methods for Preparation of Optically Active Indanones or Optically Active Indanols Using These
AU2012204839A1 (en) * 2011-01-07 2013-08-22 H. Lundbeck A/S Method for resolution of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan- 1-yl)-3,3-dimethyl-piperazine
PL2720989T3 (pl) 2011-06-20 2017-05-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
CN111868041A (zh) * 2018-04-06 2020-10-30 H.隆德贝克有限公司 用于制备2,2-二甲基哌嗪的方法
US20210395208A1 (en) 2018-10-29 2021-12-23 H. Lundeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
US11535600B2 (en) 2018-12-03 2022-12-27 H. Lundbeck A/S Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469108A (en) * 1973-06-25 1977-03-30 Kefalas As Thiaxanthene derivative
US4038395A (en) * 1973-06-25 1977-07-26 Kefalas A/S Compositions of and method of treating with the alpha-isomer of 2-chloro-9-[3'-(N'-2-hydroxyethylpiperazino-N)-propylidene]-thiaxanthene, carboxylic acid esters thereof and acid addition salts of these compounds
NZ196284A (en) * 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
IE55972B1 (en) * 1982-10-07 1991-03-13 Kefalas As Phenylindene derivatives,acid addition salts thereof,and methods of preparation
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
GB8427125D0 (en) * 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
EP0202322B1 (en) * 1984-12-03 1991-05-08 Hughes Aircraft Company Variable lens and birefringence compensator for continuous operation
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
DE3521761A1 (de) * 1985-06-19 1987-01-02 Bayer Ag Neue 1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
GB8628644D0 (en) * 1986-12-01 1987-01-07 Lunbeck A S H Intermediates
GB8704572D0 (en) * 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
EP0302423A3 (en) * 1987-08-07 1991-01-09 Hoechst-Roussel Pharmaceuticals Incorporated 1-phenyl-3-(1-piperazinyl)-1h-indazoles, a process and intermediates for their preparation, and the use thereof as medicaments
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
WO1991009594A1 (en) * 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
DK152090D0 (da) * 1990-06-22 1990-06-22 Lundbaek A S H Piperidylsubstituerede indolderivater
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
DK286990D0 (da) * 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101386387B1 (ko) * 2005-02-16 2014-04-25 하. 룬드벡 아크티에셀스카브 트랜스-1-((1ｒ,3ｓ)-6-클로로-3-페닐인단-1-일)-3,3-디메틸피페라진의 결정성 염기

Also Published As

Publication number Publication date
RU2114106C1 (ru) 1998-06-27
ES2148227T3 (es) 2000-10-16
GR3034396T3 (en) 2000-12-29
IL105464A0 (en) 1993-08-18
NO944090D0 (no) 1994-10-27
AU4059993A (en) 1993-11-29
ZA932840B (en) 1993-11-23
FI945042A (fi) 1994-10-26
HK1013816A1 (en) 1999-09-10
SK129394A3 (en) 1995-05-10
NZ252098A (en) 1996-05-28
DK55192D0 (da) 1992-04-28
ATE194003T1 (de) 2000-07-15
DE69328901D1 (de) 2000-07-27
PT638073E (pt) 2000-11-30
DE69328901T2 (de) 2001-01-11
JPH07505895A (ja) 1995-06-29
HU9403098D0 (en) 1994-12-28
CZ261994A3 (en) 1995-05-17
EP0638073A1 (en) 1995-02-15
CL2003002050A1 (es) 2005-01-07
KR100267635B1 (ko) 2000-11-01
DK0638073T3 (da) 2000-11-06
CA2134566A1 (en) 1993-11-11
SK281613B6 (sk) 2001-05-10
NO944090L (no) 1994-12-20
FI945042A0 (fi) 1994-10-26
EP0638073B1 (en) 2000-06-21
CZ281676B6 (cs) 1996-12-11
WO1993022293A1 (en) 1993-11-11
IL105464A (en) 1998-01-04
RU94045948A (ru) 1996-09-10
NO306946B1 (no) 2000-01-17
HUT71419A (en) 1995-11-28
HU211909A9 (en) 1996-01-29
FI113862B (fi) 2004-06-30
CA2134566C (en) 2004-08-10
AU669709B2 (en) 1996-06-20
JP3255416B2 (ja) 2002-02-12
US5807855A (en) 1998-09-15

Similar Documents

Publication Publication Date Title
KR950701323A (ko) 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives)
SE0104334D0 (sv) Therapeutic agents
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
HUP0105428A2 (hu) Aril vagy heteroaril-azolilkarbinol-származékok alkalmazása a P-anyag feleslege által közvetített rendellenességek kezelésére alkalmas gyógyszerkészítmények előállítására
RU2009136592A (ru) Терапевтические агенты
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
RU2004126613A (ru) Замещенные индолы в качестве агонистов альфа-1
RU2007125660A (ru) Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
AR029821A1 (es) Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
NZ526150A (en) Serotonergic agents
RU2006105782A (ru) Производные 1-сульфонилиндола, их получение и их применение в качестве лигандов 5-нт-6
AR032475A1 (es) Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprende
KR950704234A (ko) 아미노메틸인단, -벤조푸란 및 -벤조티오펜(aminomethylindans, -benzofuranes and -benzothiophenes)
AR028475A1 (es) Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
AR019859A1 (es) Derivados diaza-espiro[3,5]nonano, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y el uso de los mismos para la preparacion de un medicamento
CA2417082A1 (en) New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
BRPI0508404A (pt) derivado de (indol-3-il)-heterociclo, composição farmacêutica, uso de um derivado de (indol-3-il)-heterociclo, e método de tratamento da dor
KR910004559A (ko) 중추 신경계에 작용하는 무스카린성 약제인 4-(n-치환 아미노)-2-부티닐-1-우레아 및 티오우레아와 그의 유도체
KR910004550A (ko) 중추 신경계에 작용하는 무스카린성 약제인 4-(n-치환아미노)-2-부티닐-1-카르바메이트 및 티오카르바메이트와 그의 유도체
DK1082116T3 (da) Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme
JPS60202887A (ja) ジアゼピノインドール類、その製造法および医薬
MX2023004297A (es) Derivados de 2-oxo-dihidroquinolin-3-carboxamida como moduladores del receptor gaba tipo a.
CA2373856A1 (en) 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of drug misuse or addictive disorders
Fang et al. Imidazo[ 1, 2-A] Pyridine Anxiolytics

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120620

Year of fee payment: 13

EXPY Expiration of term